A Phase 3 interventional study of AVP-786 and Placebo in Agitation in Patients With Dementia of the Alzheimer's Type, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 126 sites in 6 countries. Open to participants aged 50 Years to 90 Years. Per ClinicalTrials.gov, last updated 2023-02-13.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Dementia by Otsuka Holdings Co., Ltd. — none open to participants now, none under way, none of them phase 3. Dementia · Otsuka Holdings Co., Ltd..
Among the 11 studies in Dementia by Otsuka Holdings Co., Ltd., this one is the 5th largest by enrollment of the 10 interventional ones that give a count, is one of 3 that started in 2015, is one of 8 in phase 3, and was the 7th registered.
2,376 studies on the registry are indexed under Dementia; 573 are open to participants now.
Browse Dementia studies →None of the 11 studies in Dementia by Otsuka Holdings Co., Ltd. is open now. The open studies under Dementia, anywhere →
Of the 382 Dementia studies recruiting now, 243 (64%) set no upper age limit and 25 (7%) stop at 75 or younger; 16 take children under 18; 163 take healthy volunteers.
This study: 50 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 1 · Phase 3 9 · Phase 4 1
First in 2003; this study’s year is marked. 3 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 387 is above the median of 90 across 1,762 interventional studies indexed under Dementia.
Median enrollment 377 across the 10 interventional studies, 450 across the 1 observational. Of the 11 that completed or were terminated, 8 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Dementia by Otsuka Holdings Co., Ltd., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Participants with agitation secondary to dementia of the Alzheimer's type. The diagnosis of probable Alzheimer's disease (AD) was to be based on the "2011 Diagnostic Guidelines for Alzheimer's Disease" issued by the National Institute on Aging (NIA)-Alzheimer's Association (AA) workgroups.
Eligible participants for this study must have had a diagnosis of probable AD and must have had clinically meaningful agitation secondary to AD.
This was to be a multicenter, randomized, placebo-controlled study, consisting of 12 weeks of treatment.
Approximately 380 participants were to be enrolled at approximately 60 centers in North America.
Study medication was to be administered orally twice-daily from Day 1 through Day 85. Screening was to occur within approximately 4 weeks prior to randomization. Following screening procedures for assessment of inclusion and exclusion criteria, eligible participants were to be randomized into the study.
2,376 studies on the registry are indexed under Dementia; 573 are open to participants now.
This study's enrollment of 387 is above the median of 90 across 1,762 interventional studies indexed under Dementia.
Browse Dementia studies →Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
Compared within Dementia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Psychomotor Agitation. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received matching placebo orally twice daily (BID) for 6 weeks (Days 1-42) in Stage 1. Participants who completed Stage 1 were eligible to Participate in Stage 2.
Drug: Placebo
Participants received AVP-786-18 mg orally once daily (QD) in the morning and placebo orally QD in the evening for the first 7 days, followed by AVP-786-18 mg orally BID for the remaining 5 weeks (Days 8-42). Participants who completed Stage 1 were eligible to participate in Stage 2.
Drug: AVP-786
Participants received AVP-786-18 mg orally QD in the morning and placebo orally QD in the evening for the first 7 days, followed by AVP-786-18 mg orally BID for 2 weeks (Days 8-21). From Day 22, participants received AVP-786-28 mg orally BID for the remaining 3 weeks. Participants who completed Stage 1 were eligible to participate in Stage 2.
Drug: AVP-786
Participants who received matching placebo orally BID for 6 consecutive weeks in Stage 1 were re-randomized in Stage 2 to receive the study drug or placebo from Day 43 to Day 85.
Drug: Placebo
Participants who received AVP-786-18 mg in Stage 1 continued to receive AVP-786-18 mg orally BID for the 6 weeks (Days 43-85) in Stage 2..
Drug: AVP-786 · Drug: Placebo
Participants who received AVP-786-28 mg in Stage 1 continued to receive AVP-786-28 mg orally BID for 6 weeks (Days 43-85) in Stage 2
Drug: AVP-786 · Drug: Placebo
Participants who were placebo responders or non-responders in Stage 1 received AVP-786-18 for 1 week, orally, QD, followed by AVP-786-18 BID for 2 weeks; followed by AVP-786-28 BID for the last 3 weeks.
Drug: AVP-786 · Drug: Placebo
Participants who were placebo responders or non-responders in Stage 1 received AVP-786-28 for 1 week, orally, QD, followed by AVP-786-28 BID for 2 weeks; followed by AVP-786-28 BID for the last 3 weeks.
Drug: AVP-786 · Drug: Placebo
Drug pages: Deudextromethorphan · Quinidine
Stage 1 and Stage 2: Change From Baseline in the Cohen-Mansfield Agitation Inventory (CMAI) Composite Score to Week 6 and Week 12
The CMAI score is used to assess the frequency of manifestations of agitated behaviors in participants. The CMAI consists of 29 agitated behaviors that are rated on a 7-point scale of frequency: 1, never; 2, less than once a week; 3, once or twice a week; 4, several times a week; 5, once or twice a day; 6, several times a day; 7, several times an hour. The CMAI total score ranges from 29 to 203. Higher scores indicate worsening of the condition. Change from Baseline was calculated as the post-Baseline score minus the Baseline score.
Time frame: Stage 1: Baseline, Week 6; Stage 2: Baseline (Week 6), Week 12
Least Squares Mean Modified Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (mADCS-CGIC)-Agitation Score at Week 6 and Week 12
The intent of the ADCS version of the CGIC is to provide a means to reliably assess the global impression of change from Baseline in a clinical trial. The mADCS-CGIC is a modification of the ADCS-CGIC instrument that focuses specifically on agitation. The participants are asked to rate their impression of change from Baseline as: 1, marked improvement; 2, moderate improvement; 3, minimal improvement; 4, no change; 5, minimal worsening; 6, moderate worsening; 7, marked worsening. Baseline was defined as the last non-missing assessment prior to Stage 1 randomization. Treatment effects were estimated at each stage by analysis of covariance (ANCOVA) with fixed effects for treatment, Baseline CMAI Total score, and in the Stage 1 model, Baseline NPI AA (≤ 6 versus \[vs\] \> 6), risk assessments for falls (normal/mild vs moderate/severe), Baseline concomitant use of antipsychotic medications (yes vs no). Missing values were imputed by last observation carried forward (LOCF) within each stage.
Time frame: Stage 1 Week 6; Stage 2 Week 12
Stage 1 and Stage 2: Change From Baseline in the Neuropsychiatric Inventory (NPI) Agitation/Aggression Domain Score to Week 6 and Week 12
The NPI is a retrospective interview covering 12 neuropsychiatric symptom domains and is used to evaluate psychopathology, neuropsychiatric manifestations, and caregiver distress. The Agitation/Aggression domain is designed to collect information on the behavioral aspects of agitation/aggression in participants with probable Alzheimer's Disease (AD) and clinically meaningful agitation secondary to AD. Each NPI domain is rated by the caregiver for symptom frequency and severity. Symptom frequency is rated as: 1, occasionally; 2, often; 3, frequently; 4, very frequently. Symptom severity is rated as: 1, mild; 2, moderate; 3, severe. The total domain score is calculated as the frequency score multiplied by the severity score and thus ranges from 1 to 12. Higher scores indicate worsening symptoms. Change from Baseline was calculated as the post-Baseline score minus the Baseline score.
Time frame: Stage 1: Baseline, Week 6; Stage 2: Baseline (Week 6), Week 12
Stage 1 and Stage 2: Change From Baseline in the NPI Caregiver Distress Score to Week 6 and Week 12
The NPI is a retrospective interview covering 12 neuropsychiatric symptom domains and is used to evaluate caregiver distress. Each NPI domain is rated by the caregiver for symptom frequency and severity. Symptom frequency is rated as: 1, occasionally; 2, often; 3, frequently; 4, very frequently. Symptom severity is rated as: 1, mild; 2, moderate; 3, marked severe. The total caregiver distress score is calculated as the frequency score multiplied by the severity score and thus ranges from 1 to 12. Higher scores indicate worsening symptoms. Change from Baseline was calculated as the post-Baseline score minus the Baseline score.
Time frame: Stage 1: Baseline, Week 6; Stage 2: Baseline (Week 6), Week 12
Stage 1 and Stage 2: Change From Baseline in the NPI Aberrant Motor Behavior Domain Score to Week 6 and Week 12
The NPI is a retrospective interview covering 12 neuropsychiatric symptom domains and is used to evaluate aberrant motor behavior. Each NPI domain is rated by the caregiver for symptom frequency and severity. Symptom frequency is rated as: 1, occasionally; 2, often; 3, frequently; 4, very frequently. Symptom severity is rated as: 1, mild; 2, moderate; 3, severe. The total domain score is calculated as the frequency score multiplied by the severity score and thus ranges from 1 to 12. Higher scores indicate worsening of the symptoms. Change from Baseline was calculated as the post-Baseline score minus the Baseline score.
Time frame: Stage 1: Baseline, Week 6; Stage 2: Baseline (Week 6), Week 12
Stage 1 and Stage 2: Change From Baseline in the Zarit Burden Interview (ZBI) Score to Week 6 and Week 12
The ZBI is a 22-item scale used to assess the impact of a participant with dementia and also other illnesses on the caregiver's burden. For each item of the scale, the caregiver indicates how often they feel the burden (never, rarely, sometimes, quite frequently, or nearly always). The score ranges from 0 to 88 and is determined by adding the numbered responses of the individual items. Higher scores indicate greater caregiver distress. Change from Baseline was calculated as the post-Baseline score minus the Baseline score. Treatment effects were estimated at each stage by ANCOVA with fixed effects for treatment, Baseline, and in the Stage 1 model, Baseline NPI AA (≤ 6 versus \> 6), risk assessments for falls (normal/mild versus moderate/severe), Baseline concomitant use of antipsychotic medications (yes versus no). Missing values were imputed by LOCF within each stage.
Time frame: Stage 1: Baseline, Week 6; Stage 2: Baseline (Week 6), Week 12
Stage 1 and Stage 2: Change From Baseline in the NPI Irritability/Lability Domain Score to Week 6 and Week 12
The NPI is a retrospective interview covering 12 neuropsychiatric symptom domains, including the irritability/lability domain score. Each NPI domain is rated by the caregiver for symptom frequency and severity. Symptom frequency is rated as: 1, occasionally; 2, often; 3, frequently; 4, very frequently. Symptom severity is rated as: 1, mild; 2, moderate; 3, severe. The total domain score is calculated as the frequency score multiplied by the severity score and thus ranges from 1 to 12. Higher scores indicate worsening of the symptoms. Change from Baseline was calculated as the post-Baseline score minus the Baseline score.
Time frame: Stage 1: Baseline, Week 6; Stage 2: Baseline (Week 6), Week 12
Stage 1 and Stage 2: Change From Baseline in the NPI Total Score to Week 6 and Week 12
NPI evaluates both frequency and severity of 12 neuropsychiatric disturbances including delusions, hallucinations, agitation/aggression, depression/dysphoria, anxiety, elation/euphoria, apathy/indifference, disinhibition, irritability/lability, motor disturbance, nighttime behaviors, as well as appetite/eating. Total domain score= frequency x severity and thus ranges from 1 to 12. NPI domain is rated by caregiver for symptom frequency and severity. Frequency is rated as: 1=occasionally, 2=often, 3= frequently, and 4=very frequently. Severity is rated as: 1=mild; 2= moderate, and 3=severe. Frequency and severity rating scales has defined anchor points to enhance reliability of caregiver responses. Caregiver distress is rated for each positive neuropsychiatric symptom using following anchored scores. It is rated as 0=not at all, 1=minimal, 3=moderate, 4=severe, 5=very severe. Total score is calculated by adding the individual Item scores, to yield a possible total scores of 0 to 144.
Time frame: Stage 1: Baseline, Week 6; Stage 2: Baseline (Week 6), Week 12
Stage 1 and Stage 2: Change From Baseline in the Clinical Global Impression of Severity of Illness (CGIS)-Agitation Domain Score to Week 6 and Week 12
The CGIS-Agitation is an observer-rated scale that measures illness severity. CGIS is used to assess the severity of agitation. The CGIS score is rated on a 7-point scale (1 = normal, not at all ill; 7 = among the most extremely ill participants). Change from Baseline was calculated as the post-Baseline score minus the Baseline score. Treatment effects were estimated at each stage by ANCOVA with fixed effects for treatment, Baseline, and in the Stage 1 model, Baseline NPI AA (≤ 6 versus \> 6), risk assessments for falls (normal/mild versus moderate/severe), Baseline concomitant use of antipsychotic medications (yes versus no). Missing values were imputed by LOCF within each stage.
Time frame: Stage 1: Baseline, Week 6; Stage 2: Baseline (Week 6), Week 12
Stage 1 and Stage 2: Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) Rating at Week 6 and Week 12
The ADCS-CGIC rating scale provides a reliable means to assess change from a Baseline level of global function within the time frame of the trial. ADCS-CGIC-Overall focuses on the clinician's observations of change in the participant's cognitive, functional, and behavioral performance. The ADCS-CGIC-Overall responses (1-7) are rated as: 1 = marked improvement, 2 = moderate improvement, 3 = minimal improvement, 4 = no change, 5 = minimal worsening, 6 = moderate worsening, or 7 = marked worsening. Treatment effects were estimated at each stage by ANCOVA with fixed effects for treatment, Baseline CMAI Total score, and in the Stage 1 model, Baseline NPI AA (≤ 6 versus \> 6), risk assessments for falls (normal/mild versus moderate/severe), Baseline concomitant use of antipsychotic medications (yes versus no). Missing values were imputed by LOCF within each stage.
Time frame: Stage 1: Baseline, Week 6; Stage 2: Baseline (Week 6), Week 12
Stage 1 and Stage 2: Patient Global Impression of Change (PGIC) Score at Week 6 and Week 12
The PGIC is a 7-point (1-7) scale used to assess treatment response: 1 = very much improved, = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, or 7 = very much worse. Treatment effects were estimated at each stage by ANCOVA with fixed effects for treatment, Baseline CMAI Total score, and in the Stage 1 model, Baseline NPI AA (≤ 6 versus \> 6), risk assessments for falls (normal/mild versus moderate/severe), Baseline concomitant use of antipsychotic medications (yes vs no). Missing values were imputed by LOCF within each stage.
Time frame: Stage 1: Baseline, Week 6; Stage 2: Baseline (Week 6), Week 12
Stage 1 and Stage 2: Change From Baseline in the Dementia Quality of Life (DEMQOL) Score to Week 6 and Week 12
The DEMQOL scale is used to evaluate health-related QOL in participants with dementia and their caregivers. There are 2 versions of the DEMQOL: a 28-item version (rated by the participant); and a 31-item version (DEMQOL-proxy, rated by the caregiver). Both versions are recommended for evaluating participants (and their caregivers) with mild to moderate dementia. The DEMQOL total score ranges from 28 to 112. The DEMQOL-proxy is used for participants with severe dementia; the total score ranges from 31 to 124. For both versions, higher scores indicate greater QOL. Change from Baseline was calculated as the post-Baseline score minus the Baseline score. Treatment effects were estimated at each stage by ANCOVA with fixed effects for treatment, Baseline, and in the Stage 1 model, Baseline NPI AA (≤ 6 vs \> 6), risk assessments for falls (normal/mild vs moderate/severe), Baseline concomitant use of antipsychotic medications (yes vs no). Missing values were imputed by LOCF within each stage.
Time frame: Stage 1: Baseline, Week 6; Stage 2: Baseline (Week 6), Week 12
Stage 1 and Stage 2: Change From Baseline in the Cornell Scale for Depression in Dementia (CSDD) Score to Week 6 and Week 12
The CSDD scale is used to assess signs/symptoms of major depression in participants with dementia. CSDD has 19 items, and each item is rated for severity on the following scale of 0 to 2 (0 =absent, 1= mild/intermittent 2=severe). CSDD score is calculated by summing non-missing scores from each item score. The scale ranges from 0-no depression to 38 maximum depressions. Scores above 10 indicate a probable major depression, above 18 indicate a definite major depression, and below 6 as a rule are associated with the absence of significant depressive symptoms. Higher score indicated maximum depression.
Time frame: Stage 1: Baseline, Week 6; Stage 2: Baseline (Week 6), Week 12
Stage 2: Percentage of Participants With General Medical Health Rating (GMHR) Score
The GMHR is a global clinical rating for medical health, designed to quantify in a single number (1 to 4) the severity of general comorbidity in a participant with dementia. The ratings are: 1 = poor; 2 = fair; 3 = good; 4 = excellent to very good. Data was collected for the treatment arm groups as pre-specified in the protocol for this outcome measure.
Time frame: Baseline; Week 12
Stage 1 and Stage 2: Change From Baseline in the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) Score to Week 6 and Week 12
The ADAS is designed to evaluate the cognitive and non-cognitive behavioral dysfunction characteristics of participants with AD. The cognitive subscale (ADAS-cog) consists of 11 subsets related to memory, praxis, and language. ADAS-cog scores range from 0 to 70. Higher scores indicate greater cognitive impairment. The ADAS-cog is assessed for participants with an Mini-Mental State Examination (MMSE) score of ≥10 at the Baseline Visit. Change from Baseline was calculated as the post-Baseline score minus the Baseline score. Treatment effects were estimated at each stage by ANCOVA with fixed effects for treatment, Baseline, and in the Stage 1 model, Baseline NPI AA (≤ 6 versus \> 6), risk assessments for falls (normal/mild versus moderate/severe), Baseline concomitant use of antipsychotic medications (yes vs no). Missing values were imputed by LOCF within each stage.
Time frame: Stage 1: Baseline, Week 6; Stage 2: Baseline (Week 6), Week 12
Stage 1: Resource Utilization in Dementia (RUD): Percentage of Caregiver Who Reported That Their Responsibilities Affected Their Work and Who Visited Health Care Professionals
RUD evaluates dementia participants utilization of formal and informal healthcare resources, including hospitalizations and doctor visits, living assistance, and time spent by nonprofessional caregivers. The RUD is administered as a semi-structured interview with the participant's primary caregiver and contains 2 sections; one focusing on caregiver impact (loss of work and leisure time incurred by caregiver) and the other focusing on the participant's use of healthcare resources. Information of caregivers who reported their responsibilities affected their work and who visited healthcare professionals from the interviews during Stage 1 is reported for this outcome measure. Data was collected for the treatment arm groups as pre-specified in the protocol for this outcome measure.
Time frame: Stage 1: Week 6
Stage 2: Resource Utilization in Dementia (RUD): Percentage of Caregiver Who Reported That Their Responsibilities Affected Their Work and Who Visited Health Care Professionals
RUD evaluates dementia participants utilization of formal and informal healthcare resources, including hospitalizations and doctor visits, living assistance, and time spent by nonprofessional caregivers. The RUD is administered as a semi-structured interview with the participant's primary caregiver and contains 2 sections; one focusing on caregiver impact (loss of work and leisure time incurred by caregiver) and the other focusing on the participant's use of healthcare resources. Information of caregivers who reported their responsibilities affected their work and who visited healthcare professionals from the interviews during Stage 2 is reported for this outcome measure. Data was collected for the treatment arm groups as pre-specified in the protocol for this outcome measure.
Time frame: Stage 2: Week 12
Stage 1: Resource Utilization in Dementia (RUD): Number of Hours Per Day the Caregiver Spent Assisting the Participant
RUD evaluates dementia participants utilization of formal, informal healthcare resources, including hospitalizations, doctor visits, living assistance, time spent by nonprofessional caregivers. Information on hours per day caregiver spent assisting participant from interviews during Stage 1 is reported for this outcome measure, where the following questions (Q), Q1= On typical care day during last 30 days, how much time per day did you assist participant with tasks such as toilet visits, eating, dressing, grooming, walking, bathing? Q2= On typical care day during the last 30 days, how much time per day did you assist participant with tasks as (shopping, food preparation, housekeeping, laundry, transportation, taking medication, managing financial matters?; Q3= On typical care day during last 30 days, how much time per day did you spend supervising (preventing dangerous events)?(Q3). Data is collected for treatment arm groups as pre-specified in protocol for this outcome measure.
Time frame: Stage 1: Week 6
Stage 2: Resource Utilization in Dementia (RUD): Number of Hours Per Day the Caregiver Spent Assisting the Participant
RUD evaluates dementia participants utilization of formal, informal healthcare resources, including hospitalizations, doctor visits, living assistance, time spent by nonprofessional caregivers. Information on hours per day caregiver spent assisting participant from interviews during Stage 1 is reported for this outcome measure, where the following questions (Q), Q1= On typical care day during last 30 days, how much time per day did you assist participant with tasks such as toilet visits, eating, dressing, grooming, walking, bathing? Q2= On typical care day during the last 30 days, how much time per day did you assist participant with tasks as (shopping, food preparation, housekeeping, laundry, transportation, taking medication, managing financial matters?; Q3= On typical care day during last 30 days, how much time per day did you spend supervising (preventing dangerous events)?(Q3). Data is collected for treatment arm groups as pre-specified in protocol for this outcome measure.
Time frame: Stage 2: Week 12
Stage 1: Resource Utilization in Dementia (RUD) Score: Number of Days the Caregiver Spent Assisting the Participant
RUD evaluates dementia participants utilization of formal, informal healthcare resources, including hospitalizations, doctor visits, living assistance, time spent by nonprofessional caregivers. Information on days caregiver spent assisting participant from interviews during Stage 1 is reported for outcome measure, where following questions (Q), Q1= During last 30 days, how many days did you spend providing these (toilet visits, eating, dressing, grooming, walking, bathing) services to participant?; Q2= On typical care day during last 30 days, how much time per day did you assist participant with tasks such as shopping, food preparation, housekeeping, laundry, transportation, taking medication, managing financial matters?; Q3= During last 30 days, how many days did you spend providing these services (supervising) to the participant?. Data is collected for the treatment arm groups as pre-specified in the protocol for this outcome measure.
Time frame: Stage 1: Week 6
12-Week Parallel Group: Resource Utilization in Dementia (RUD) Score: Number of Days the Caregiver Spent Assisting the Participant
RUD evaluates dementia participants utilization of formal, informal healthcare resources, including hospitalizations, doctor visits, living assistance, time spent by nonprofessional caregivers. Information on days caregiver spent assisting participant from interviews during Stage 1 is reported for outcome measure, where following questions (Q), Q1= During last 30 days, how many days did you spend providing these (toilet visits, eating, dressing, grooming, walking, bathing) services to participant?; Q2= On typical care day during last 30 days, how much time per day did you assist participant with tasks such as shopping, food preparation, housekeeping, laundry, transportation, taking medication, managing financial matters?; Q3= During last 30 days, how many days did you spend providing these services (supervising) to the participant?. Data is collected for the treatment arm groups as pre-specified in the protocol for this outcome measure.
Time frame: 12-Week Parallel Group: Week 12
Total of 695 participants were screened of these, 308 participants failed screening, 387 participants were randomized out of which 382 participants had at least 1 post baseline efficacy assessment. (Modified Intent-to-Treat { mITT} population).
| Milestone | Stage 1: Placebo | Stage 1: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg) | Stage 1: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg) | Stage 2: Placebo | Stage 1: Placebo to: Stage 2: AVP-786-28 d6-DM 18 mg/Q 4.9 mg | Stage 1: Placebo to: Stage 2: AVP-786-28 d6 DM 28 mg/Q 4.9 mg | Stage 1: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg) to: Stage 2: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg) | Stage 1: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg) to Stage 2: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg) |
|---|---|---|---|---|---|---|---|---|
| Started | 194 | 96 | 97 | 0 | 0 | 0 | 0 | 0 |
| Completed | 194 | 96 | 97 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Stage 1: Placebo | Stage 1: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg) | Stage 1: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg) | Stage 2: Placebo | Stage 1: Placebo to: Stage 2: AVP-786-28 d6-DM 18 mg/Q 4.9 mg | Stage 1: Placebo to: Stage 2: AVP-786-28 d6 DM 28 mg/Q 4.9 mg | Stage 1: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg) to: Stage 2: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg) | Stage 1: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg) to Stage 2: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg) |
|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 63 | 96 | 97 | 65 | 66 |
| Completed | 0 | 0 | 0 | 56 | 86 | 92 | 59 | 55 |
| Not completed | 0 | 0 | 0 | 7 | 10 | 5 | 6 | 11 |
| Withdrew: Adverse event | 0 | 0 | 0 | 2 | 6 | 1 | 1 | 5 |
| Withdrew: Death | 0 | 0 | 0 | 1 | 1 | 0 | 2 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol deviation | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Study participant withdrawal by parent or guardian | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 4 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 1 | 0 | 3 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 2 | 0 | 2 | 1 |
| Withdrew: Reason not specified | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
The CMAI score is used to assess the frequency of manifestations of agitated behaviors in participants. The CMAI consists of 29 agitated behaviors that are rated on a 7-point scale of frequency: 1, never; 2, less than once a week; 3, once or twice a week; 4, several times a week; 5, once or twice a day; 6, several times a day; 7, several times an hour. The CMAI total score ranges from 29 to 203. Higher scores indicate worsening of the condition. Change from Baseline was calculated as the post-Baseline score minus the Baseline score.
| units on a scale | Stage 1: Placebo | Stage 1: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg) | Stage 1: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg) | Stage 1: Placebo Non-responders to Stage 2: Placebo | Stage 1: Placebo Non-responders to Stage 2: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg) | Stage 1: Placebo Non-responders to Stage 2: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg) |
|---|---|---|---|---|---|---|
| Stage 1 Baseline | 73.9 ± 22.23 | 72.3 ± 23.08 | 71.7 ± 23.57 | — | — | — |
| Change from Baseline at Week 6 | -10.7 ± 15.29 | -13.9 ± 16.70 | -10.3 ± 13.54 | — | — | — |
| Stage 2 Baseline | — | — | — | 66.0 ± 24.71 | 68.9 ± 20.79 | 65.3 ± 19.36 |
| Change from Baseline at Week 12 | — | — | — | -1.6 ± 11.08 | -5.6 ± 11.78 | -4.9 ± 12.13 |
The intent of the ADCS version of the CGIC is to provide a means to reliably assess the global impression of change from Baseline in a clinical trial. The mADCS-CGIC is a modification of the ADCS-CGIC instrument that focuses specifically on agitation. The participants are asked to rate their impression of change from Baseline as: 1, marked improvement; 2, moderate improvement; 3, minimal improvement; 4, no change; 5, minimal worsening; 6, moderate worsening; 7, marked worsening. Baseline was defined as the last non-missing assessment prior to Stage 1 randomization. Treatment effects were estimated at each stage by analysis of covariance (ANCOVA) with fixed effects for treatment, Baseline CMAI Total score, and in the Stage 1 model, Baseline NPI AA (≤ 6 versus \[vs\] \> 6), risk assessments for falls (normal/mild vs moderate/severe), Baseline concomitant use of antipsychotic medications (yes vs no). Missing values were imputed by last observation carried forward (LOCF) within each stage.
| score on a scale | Stage 1: Placebo | Stage 1: AVP-786-18 d6-DM 18 mg/Q 4.9 mg | Stage 1: AVP-786-28 d6-DM 28 mg/Q 4.9 mg | Stage 1: Placebo Non-responders to Stage 2: Placebo | Stage 1: Placebo Non-responders to Stage 2: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg) | Stage 1: Placebo Non-responders to Stage 2: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg) |
|---|---|---|---|---|---|---|
| Stage 1 Week 6 | 3.4 ± 1.13 | 3.2 ± 1.24 | 3.3 ± 1.12 | — | — | — |
| Stage 2 Week 12 | — | — | — | 3.9 ± 0.18 | 3.3 ± 0.18 | 3.5 ± 0.17 |
The NPI is a retrospective interview covering 12 neuropsychiatric symptom domains and is used to evaluate psychopathology, neuropsychiatric manifestations, and caregiver distress. The Agitation/Aggression domain is designed to collect information on the behavioral aspects of agitation/aggression in participants with probable Alzheimer's Disease (AD) and clinically meaningful agitation secondary to AD. Each NPI domain is rated by the caregiver for symptom frequency and severity. Symptom frequency is rated as: 1, occasionally; 2, often; 3, frequently; 4, very frequently. Symptom severity is rated as: 1, mild; 2, moderate; 3, severe. The total domain score is calculated as the frequency score multiplied by the severity score and thus ranges from 1 to 12. Higher scores indicate worsening symptoms. Change from Baseline was calculated as the post-Baseline score minus the Baseline score.
| units on a scale | Stage 1: Placebo | Stage 1: AVP-786-18 d6-DM 18 mg/Q 4.9 mg | Stage 1: AVP-786-28 d6-DM 28 mg/Q 4.9 mg | Stage 1: Placebo Non-responders to Stage 2: Placebo | Stage 1: Placebo Non-responders to Stage 2: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg) | Stage 1: Placebo Non-responders to Stage 2: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg) |
|---|---|---|---|---|---|---|
| Stage 1 Baseline | 7.1 ± 2.39 | 6.5 ± 1.94 | 7.2 ± 2.42 | — | — | — |
| Change from Baseline at Week 6 | -1.8 ± 3.58 | -2.0 ± 3.03 | -2.1 ± 2.94 | — | — | — |
| Stage 2 Baseline | — | — | — | 6.9 ± 2.84 | 6.3 ± 2.71 | 6.3 ± 2.81 |
| Change from Baseline at Week 12 | — | — | — | -1.7 ± 3.00 | -0.8 ± 3.15 | -0.9 ± 3.35 |
The NPI is a retrospective interview covering 12 neuropsychiatric symptom domains and is used to evaluate caregiver distress. Each NPI domain is rated by the caregiver for symptom frequency and severity. Symptom frequency is rated as: 1, occasionally; 2, often; 3, frequently; 4, very frequently. Symptom severity is rated as: 1, mild; 2, moderate; 3, marked severe. The total caregiver distress score is calculated as the frequency score multiplied by the severity score and thus ranges from 1 to 12. Higher scores indicate worsening symptoms. Change from Baseline was calculated as the post-Baseline score minus the Baseline score.
| units on a scale | Stage 1: Placebo | Stage 1: AVP-786-18 d6-DM 18 mg/Q 4.9 mg | Stage 1: AVP-786-28 d6-DM 28 mg/Q 4.9 mg | Stage 1: Placebo Non-responders to Stage 2: Placebo | Stage 1: Placebo Non-responders to Stage 2: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg) | Stage 1: Placebo Non-responders to Stage 2: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg) |
|---|---|---|---|---|---|---|
| Stage 1 Baseline | 18.87 ± 9.026 | 18.90 ± 9.266 | 18.88 ± 10.015 | — | — | — |
| Change from Baseline at Week 6 | -4.31 ± 7.979 | -5.48 ± 8.559 | -4.83 ± 7.736 | — | — | — |
| Stage 2 Baseline | — | — | — | 17.33 ± 9.010 | 15.95 ± 7.241 | 16.89 ± 7.416 |
| Change from Baseline at Week 12 | — | — | — | -0.73 ± 6.533 | -1.67 ± 5.666 | 0.44 ± 7.265 |
The NPI is a retrospective interview covering 12 neuropsychiatric symptom domains and is used to evaluate aberrant motor behavior. Each NPI domain is rated by the caregiver for symptom frequency and severity. Symptom frequency is rated as: 1, occasionally; 2, often; 3, frequently; 4, very frequently. Symptom severity is rated as: 1, mild; 2, moderate; 3, severe. The total domain score is calculated as the frequency score multiplied by the severity score and thus ranges from 1 to 12. Higher scores indicate worsening of the symptoms. Change from Baseline was calculated as the post-Baseline score minus the Baseline score.
| units on a scale | Stage 1: Placebo | Stage 1: AVP-786-18 d6-DM 18 mg/Q 4.9 mg | Stage 1: AVP-786-28 d6-DM 28 mg/Q 4.9 mg | Stage 1: Placebo Non-responders to Stage 2: Placebo | Stage 1: Placebo Non-responders to Stage 2: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg) | Stage 1: Placebo Non-responders to Stage 2: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg) |
|---|---|---|---|---|---|---|
| Stage 1 Baseline | 5.1 ± 3.94 | 4.9 ± 3.77 | 5.1 ± 4.07 | — | — | — |
| Change from Baseline at Week 6 Stage 2 Baseline | -0.9 ± 3.62 | -1.6 ± 3.74 | -0.7 ± 3.86 | — | — | — |
| Stage 2 Baseline | — | — | — | 5.2 ± 3.79 | 4.0 ± 3.87 | 4.3 ± 4.32 |
| Change from Baseline at Week 12 | — | — | — | -0.4 ± 2.16 | 0.6 ± 3.24 | 1.1 ± 3.54 |
The ZBI is a 22-item scale used to assess the impact of a participant with dementia and also other illnesses on the caregiver's burden. For each item of the scale, the caregiver indicates how often they feel the burden (never, rarely, sometimes, quite frequently, or nearly always). The score ranges from 0 to 88 and is determined by adding the numbered responses of the individual items. Higher scores indicate greater caregiver distress. Change from Baseline was calculated as the post-Baseline score minus the Baseline score. Treatment effects were estimated at each stage by ANCOVA with fixed effects for treatment, Baseline, and in the Stage 1 model, Baseline NPI AA (≤ 6 versus \> 6), risk assessments for falls (normal/mild versus moderate/severe), Baseline concomitant use of antipsychotic medications (yes versus no). Missing values were imputed by LOCF within each stage.
| units on a scale | Stage 1: Placebo | Stage 1: AVP-786-18 d6-DM 18 mg/Q 4.9 mg | Stage 1: AVP-786-28 d6-DM 28 mg/Q 4.9 mg | Stage 1: Placebo Non-responders to Stage 2: Placebo | Stage 1: Placebo Non-responders to Stage 2: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg) | Stage 1: Placebo Non-responders to Stage 2: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg) |
|---|---|---|---|---|---|---|
| Stage 1 Baseline | 30.9 ± 16.19 | 30.0 ± 16.96 | 33.0 ± 16.68 | — | — | — |
| Change from Baseline at Week 6 | -1.4 ± 8.22 | -2.0 ± 8.44 | -2.7 ± 9.49 | — | — | — |
| Stage 2 Baseline | — | — | — | 31.5 ± 15.24 | 32.0 ± 16.57 | 28.6 ± 16.76 |
| Change from Baseline at Week 12 | — | — | — | -1.1 ± 7.65 | 1.4 ± 8.71 | -0.5 ± 7.05 |
The NPI is a retrospective interview covering 12 neuropsychiatric symptom domains, including the irritability/lability domain score. Each NPI domain is rated by the caregiver for symptom frequency and severity. Symptom frequency is rated as: 1, occasionally; 2, often; 3, frequently; 4, very frequently. Symptom severity is rated as: 1, mild; 2, moderate; 3, severe. The total domain score is calculated as the frequency score multiplied by the severity score and thus ranges from 1 to 12. Higher scores indicate worsening of the symptoms. Change from Baseline was calculated as the post-Baseline score minus the Baseline score.
| units on a scale | Stage 1: Placebo | Stage 1: AVP-786-18 d6-DM 18 mg/Q 4.9 mg | Stage 1: AVP-786-28 d6-DM 28 mg/Q 4.9 mg | Stage 1: Placebo Non-responders to Stage 2: Placebo | Stage 1: Placebo Non-responders to Stage 2: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg) | Stage 1: Placebo Non-responders to Stage 2: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg) |
|---|---|---|---|---|---|---|
| Stage 1 Baseline | 5.1 ± 3.33 | 5.1 ± 3.62 | 5.2 ± 3.39 | — | — | — |
| Change from Baseline at Week 6 | -1.1 ± 3.84 | -1.9 ± 3.71 | -1.4 ± 3.62 | — | — | — |
| Stage 2 Baseline | — | — | — | 4.5 ± 3.99 | 5.3 ± 3.54 | 5.2 ± 3.64 |
| Change from Baseline at Week 12 | — | — | — | 0.2 ± 3.19 | -1.3 ± 3.88 | -0.9 ± 3.45 |
NPI evaluates both frequency and severity of 12 neuropsychiatric disturbances including delusions, hallucinations, agitation/aggression, depression/dysphoria, anxiety, elation/euphoria, apathy/indifference, disinhibition, irritability/lability, motor disturbance, nighttime behaviors, as well as appetite/eating. Total domain score= frequency x severity and thus ranges from 1 to 12. NPI domain is rated by caregiver for symptom frequency and severity. Frequency is rated as: 1=occasionally, 2=often, 3= frequently, and 4=very frequently. Severity is rated as: 1=mild; 2= moderate, and 3=severe. Frequency and severity rating scales has defined anchor points to enhance reliability of caregiver responses. Caregiver distress is rated for each positive neuropsychiatric symptom using following anchored scores. It is rated as 0=not at all, 1=minimal, 3=moderate, 4=severe, 5=very severe. Total score is calculated by adding the individual Item scores, to yield a possible total scores of 0 to 144.
| units on a scale | Stage 1: Placebo | Stage 1: AVP-786-18 d6-DM 18 mg/Q 4.9 mg | Stage 1: AVP-786-28 d6-DM 28 mg/Q 4.9 mg | Stage 1: Placebo Non-responders to Stage 2: Placebo | Stage 1: Placebo Non-responders to Stage 2: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg) | Stage 1: Placebo Non-responders to Stage 2: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg) |
|---|---|---|---|---|---|---|
| Stage 1 Baseline | 40.2 ± 17.95 | 39.4 ± 18.93 | 40.1 ± 19.98 | — | — | — |
| Change from Baseline at Week 6 | -9.2 ± 17.41 | -13.2 ± 17.99 | -10.6 ± 16.09 | — | — | — |
| Stage 2 Baseline | — | — | — | 39.2 ± 22.47 | 34.7 ± 14.16 | 34.6 ± 16.93 |
| Change from Baseline at Week 12 | — | — | — | -5.1 ± 14.03 | -4.4 ± 12.92 | -0.1 ± 18.82 |
The CGIS-Agitation is an observer-rated scale that measures illness severity. CGIS is used to assess the severity of agitation. The CGIS score is rated on a 7-point scale (1 = normal, not at all ill; 7 = among the most extremely ill participants). Change from Baseline was calculated as the post-Baseline score minus the Baseline score. Treatment effects were estimated at each stage by ANCOVA with fixed effects for treatment, Baseline, and in the Stage 1 model, Baseline NPI AA (≤ 6 versus \> 6), risk assessments for falls (normal/mild versus moderate/severe), Baseline concomitant use of antipsychotic medications (yes versus no). Missing values were imputed by LOCF within each stage.
| units on a scale | Stage 1: Placebo | Stage 1: AVP-786-18 d6-DM 18 mg/Q 4.9 mg | Stage 1: AVP-786-28 d6-DM 28 mg/Q 4.9 mg | Stage 1: Placebo Non-responders to Stage 2: Placebo | Stage 1: Placebo Non-responders to Stage 2: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg) | Stage 1: Placebo Non-responders to Stage 2: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg) |
|---|---|---|---|---|---|---|
| Stage 1 Baseline | 4.5 ± 0.64 | 4.3 ± 0.49 | 4.4 ± 0.70 | — | — | — |
| Change from Baseline at Week 6 | -0.5 ± 0.78 | -0.7 ± 0.97 | -0.7 ± 1.04 | — | — | — |
| Stage 2 Baseline | — | — | — | 4.4 ± 0.87 | 4.2 ± 0.77 | 4.1 ± 0.77 |
| Change from Baseline at Week 12 | — | — | — | -0.2 ± 0.58 | -0.4 ± 0.70 | -0.3 ± 1.01 |
The ADCS-CGIC rating scale provides a reliable means to assess change from a Baseline level of global function within the time frame of the trial. ADCS-CGIC-Overall focuses on the clinician's observations of change in the participant's cognitive, functional, and behavioral performance. The ADCS-CGIC-Overall responses (1-7) are rated as: 1 = marked improvement, 2 = moderate improvement, 3 = minimal improvement, 4 = no change, 5 = minimal worsening, 6 = moderate worsening, or 7 = marked worsening. Treatment effects were estimated at each stage by ANCOVA with fixed effects for treatment, Baseline CMAI Total score, and in the Stage 1 model, Baseline NPI AA (≤ 6 versus \> 6), risk assessments for falls (normal/mild versus moderate/severe), Baseline concomitant use of antipsychotic medications (yes versus no). Missing values were imputed by LOCF within each stage.
| units on a scale | Stage 1: Placebo | Stage 1: AVP-786-18 d6-DM 18 mg/Q 4.9 mg | Stage 1: AVP-786-28 d6-DM 28 mg/Q 4.9 mg | Stage 1: Placebo Non-responders to Stage 2: Placebo | Stage 1: Placebo Non-responders to Stage 2: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg) | Stage 1: Placebo Non-responders to Stage 2: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg) |
|---|---|---|---|---|---|---|
| Stage 1 Week 6 | 3.7 ± 0.11 | 3.5 ± 0.14 | 3.6 ± 0.13 | — | — | — |
| Stage 2 Week 12 | — | — | — | 4.0 ± 0.17 | 3.6 ± 0.17 | 3.7 ± 0.16 |
The PGIC is a 7-point (1-7) scale used to assess treatment response: 1 = very much improved, = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, or 7 = very much worse. Treatment effects were estimated at each stage by ANCOVA with fixed effects for treatment, Baseline CMAI Total score, and in the Stage 1 model, Baseline NPI AA (≤ 6 versus \> 6), risk assessments for falls (normal/mild versus moderate/severe), Baseline concomitant use of antipsychotic medications (yes vs no). Missing values were imputed by LOCF within each stage.
| units on a scale | Stage 1: Placebo | Stage 1: AVP-786-18 d6-DM 18 mg/Q 4.9 mg | Stage 1: AVP-786-28 d6-DM 28 mg/Q 4.9 mg | Stage 1: Placebo Non-responders to Stage 2: Placebo | Stage 1: Placebo Non-responders to Stage 2: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg) | Stage 1: Placebo Non-responders to Stage 2: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg) |
|---|---|---|---|---|---|---|
| Stage 1 Week 6 | 3.4 ± 0.12 | 3.0 ± 0.15 | 3.1 ± 0.14 | — | — | — |
| Stage 2 Week 12 | — | — | — | 3.6 ± 0.20 | 3.1 ± 0.20 | 3.3 ± 0.19 |
The DEMQOL scale is used to evaluate health-related QOL in participants with dementia and their caregivers. There are 2 versions of the DEMQOL: a 28-item version (rated by the participant); and a 31-item version (DEMQOL-proxy, rated by the caregiver). Both versions are recommended for evaluating participants (and their caregivers) with mild to moderate dementia. The DEMQOL total score ranges from 28 to 112. The DEMQOL-proxy is used for participants with severe dementia; the total score ranges from 31 to 124. For both versions, higher scores indicate greater QOL. Change from Baseline was calculated as the post-Baseline score minus the Baseline score. Treatment effects were estimated at each stage by ANCOVA with fixed effects for treatment, Baseline, and in the Stage 1 model, Baseline NPI AA (≤ 6 vs \> 6), risk assessments for falls (normal/mild vs moderate/severe), Baseline concomitant use of antipsychotic medications (yes vs no). Missing values were imputed by LOCF within each stage.
| units on a scale | Stage 1: Placebo | Stage 1: AVP-786-18 d6-DM 18 mg/Q 4.9 mg | Stage 1: AVP-786-28 d6-DM 28 mg/Q 4.9 mg | Stage 1: Placebo Non-responders to Stage 2: Placebo | Stage 1: Placebo Non-responders to Stage 2: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg) | Stage 1: Placebo Non-responders to Stage 2: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg) |
|---|---|---|---|---|---|---|
| Stage 1 Baseline | 85.7 ± 10.63 | 82.9 ± 10.22 | 84.0 ± 11.98 | — | — | — |
| Change from Baseline at Week 6 | 2.3 ± 8.26 | 3.5 ± 8.57 | 4.4 ± 10.79 | — | — | — |
| Stage 2 Baseline | — | — | — | 86.8 ± 9.96 | 90.0 ± 9.51 | 87.8 ± 10.72 |
| Change from Baseline at Week 12 | — | — | — | 2.5 ± 5.40 | 3.1 ± 9.52 | 1.1 ± 13.06 |
The CSDD scale is used to assess signs/symptoms of major depression in participants with dementia. CSDD has 19 items, and each item is rated for severity on the following scale of 0 to 2 (0 =absent, 1= mild/intermittent 2=severe). CSDD score is calculated by summing non-missing scores from each item score. The scale ranges from 0-no depression to 38 maximum depressions. Scores above 10 indicate a probable major depression, above 18 indicate a definite major depression, and below 6 as a rule are associated with the absence of significant depressive symptoms. Higher score indicated maximum depression.
| units on a scale | Stage 1: Placebo | Stage 1: AVP-786-18 d6-DM 18 mg/Q 4.9 mg | Stage 1: AVP-786-28 d6-DM 28 mg/Q 4.9 mg | Stage 1: Placebo Non-responders to Stage 2: Placebo | Stage 1: Placebo Non-responders to Stage 2: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg) | Stage 1: Placebo Non-responders to Stage 2: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg) |
|---|---|---|---|---|---|---|
| Stage 1 Baseline | 6.2 ± 2.24 | 6.3 ± 2.11 | 6.4 ± 2.19 | — | — | — |
| Change from Baseline at Week 6 | -0.3 ± 3.01 | -0.7 ± 3.09 | -0.5 ± 2.93 | — | — | — |
| Stage 2 Baseline | — | — | — | 6.6 ± 3.89 | 5.9 ± 2.78 | 6.8 ± 2.84 |
| Change from Baseline at Week 12 | — | — | — | -0.4 ± 2.56 | -0.5 ± 2.36 | -0.3 ± 3.09 |
The GMHR is a global clinical rating for medical health, designed to quantify in a single number (1 to 4) the severity of general comorbidity in a participant with dementia. The ratings are: 1 = poor; 2 = fair; 3 = good; 4 = excellent to very good. Data was collected for the treatment arm groups as pre-specified in the protocol for this outcome measure.
| percentage of participants | Stage 1: Placebo to Stage 2: Placebo | Stage 1: Placebo to: Stage 2: AVP-786-18 d6-DM 18 mg/Q 4.9 mg | Stage 1: Placebo to: Stage 2: AVP-786-28 d6 DM 28 mg/Q 4.9 mg | Stage 1: AVP-786-18 d6-DM 18 mg/Q 4.9 mg to Stage 2: AVP-786-18 d6-DM 18 mg/Q 4.9 mg | Stage 1: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg) to Stage 2: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg) |
|---|---|---|---|---|---|
| Excellent to very good | 22.6 | 20.3 | 13.8 | 20.2 | 20.6 |
| Good | 59.7 | 64.1 | 58.5 | 58.5 | 62.9 |
| Fair | 11.3 | 7.8 | 16.9 | 13.8 | 11.3 |
| Poor | 0 | 0 | 0 | 0 | 0 |
| Missing | 6.5 | 7.8 | 10.8 | 7.4 | 5.2 |
The ADAS is designed to evaluate the cognitive and non-cognitive behavioral dysfunction characteristics of participants with AD. The cognitive subscale (ADAS-cog) consists of 11 subsets related to memory, praxis, and language. ADAS-cog scores range from 0 to 70. Higher scores indicate greater cognitive impairment. The ADAS-cog is assessed for participants with an Mini-Mental State Examination (MMSE) score of ≥10 at the Baseline Visit. Change from Baseline was calculated as the post-Baseline score minus the Baseline score. Treatment effects were estimated at each stage by ANCOVA with fixed effects for treatment, Baseline, and in the Stage 1 model, Baseline NPI AA (≤ 6 versus \> 6), risk assessments for falls (normal/mild versus moderate/severe), Baseline concomitant use of antipsychotic medications (yes vs no). Missing values were imputed by LOCF within each stage.
| units on a scale | Stage 1: Placebo | Stage 1: AVP-786-18 d6-DM 18 mg/Q 4.9 mg | Stage 1: AVP-786-28 d6-DM 28 mg/Q 4.9 mg | Stage 1: Placebo Non-responders to Stage 2: Placebo | Stage 1: Placebo Non-responders to Stage 2: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg) | Stage 1: Placebo Non-responders to Stage 2: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg) |
|---|---|---|---|---|---|---|
| Stage 1 Baseline | 25.8 ± 10.10 | 26.2 ± 8.99 | 25.3 ± 8.88 | — | — | — |
| Change from Baseline at Week 6 | -0.5 ± 4.46 | -2.0 ± 4.28 | -0.5 ± 4.72 | — | — | — |
| Stage 2 Baseline | — | — | — | 26.9 ± 9.56 | 27.0 ± 9.27 | 25.3 ± 10.91 |
| Change from Baseline at Week 12 | — | — | — | -0.8 ± 5.05 | 0.3 ± 4.95 | 0.1 ± 5.47 |
RUD evaluates dementia participants utilization of formal and informal healthcare resources, including hospitalizations and doctor visits, living assistance, and time spent by nonprofessional caregivers. The RUD is administered as a semi-structured interview with the participant's primary caregiver and contains 2 sections; one focusing on caregiver impact (loss of work and leisure time incurred by caregiver) and the other focusing on the participant's use of healthcare resources. Information of caregivers who reported their responsibilities affected their work and who visited healthcare professionals from the interviews during Stage 1 is reported for this outcome measure. Data was collected for the treatment arm groups as pre-specified in the protocol for this outcome measure.
| percentage of participants | Stage 1: Placebo | Stage 1: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg) | Stage 1: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg) |
|---|---|---|---|
| Caregivers Who Reported that their Responsibilities Affected Their Work | 33.8 | 22.9 | 34.2 |
| Caregivers Who Visited Health Care Professionals | 42.2 | 31.1 | 44.8 |
RUD evaluates dementia participants utilization of formal and informal healthcare resources, including hospitalizations and doctor visits, living assistance, and time spent by nonprofessional caregivers. The RUD is administered as a semi-structured interview with the participant's primary caregiver and contains 2 sections; one focusing on caregiver impact (loss of work and leisure time incurred by caregiver) and the other focusing on the participant's use of healthcare resources. Information of caregivers who reported their responsibilities affected their work and who visited healthcare professionals from the interviews during Stage 2 is reported for this outcome measure. Data was collected for the treatment arm groups as pre-specified in the protocol for this outcome measure.
| percentage of participants | Stage 2: Placebo/Placebo | Stage 1: Placebo to: Stage 2: AVP-786-18 d6-DM 18 mg/Q 4.9 mg | Stage 1: Placebo to: Stage 2: AVP-786-28 d6 DM 28 mg/Q 4.9 mg | Stage 1: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg) to: Stage 2: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg) | Stage 1: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg) to Stage 2: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg) |
|---|---|---|---|---|---|
| Caregivers Who Reported that their Responsibilities Affected Their Work | 44.0 | 28.6 | 36.4 | 24.2 | 35.3 |
| Caregivers Who Visited Health Care Professionals | 43.1 | 30.5 | 29.3 | 26.7 | 37.0 |
RUD evaluates dementia participants utilization of formal, informal healthcare resources, including hospitalizations, doctor visits, living assistance, time spent by nonprofessional caregivers. Information on hours per day caregiver spent assisting participant from interviews during Stage 1 is reported for this outcome measure, where the following questions (Q), Q1= On typical care day during last 30 days, how much time per day did you assist participant with tasks such as toilet visits, eating, dressing, grooming, walking, bathing? Q2= On typical care day during the last 30 days, how much time per day did you assist participant with tasks as (shopping, food preparation, housekeeping, laundry, transportation, taking medication, managing financial matters?; Q3= On typical care day during last 30 days, how much time per day did you spend supervising (preventing dangerous events)?(Q3). Data is collected for treatment arm groups as pre-specified in protocol for this outcome measure.
| hours | Stage 1: Placebo | Stage 1: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg) | Stage 1: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg) |
|---|---|---|---|
| Week 6 (Q1) | 2.0 (0 to 20) | 2.0 (0 to 24) | 2.0 (0 to 15) |
| Week 6 (Q2) | 4.0 (1 to 24) | 4.0 (0 to 18) | 4.0 (1 to 15) |
| Week 6 (Q3) | 3.0 (0 to 24) | 2.0 (0 to 24) | 2.8 (0 to 24) |
RUD evaluates dementia participants utilization of formal, informal healthcare resources, including hospitalizations, doctor visits, living assistance, time spent by nonprofessional caregivers. Information on hours per day caregiver spent assisting participant from interviews during Stage 1 is reported for this outcome measure, where the following questions (Q), Q1= On typical care day during last 30 days, how much time per day did you assist participant with tasks such as toilet visits, eating, dressing, grooming, walking, bathing? Q2= On typical care day during the last 30 days, how much time per day did you assist participant with tasks as (shopping, food preparation, housekeeping, laundry, transportation, taking medication, managing financial matters?; Q3= On typical care day during last 30 days, how much time per day did you spend supervising (preventing dangerous events)?(Q3). Data is collected for treatment arm groups as pre-specified in protocol for this outcome measure.
| hours | Stage 1: Placebo to Stage 2: Placebo | Stage 1: Placebo to Stage 2: AVP-786 18 mg | Stage 1: Placebo to Stage 2: AVP-786 28 mg | Stage 1: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg) to: Stage 2: AVP-786-18 (d6-DM 18 mg/Q 4.9 mg) | Stage 1: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg) to Stage 2: AVP-786-28 (d6-DM 28 mg/Q 4.9 mg) |
|---|---|---|---|---|---|
| Week 12 (Q1) | 1.5 (0 to 15) | 2.0 (0 to 7) | 2.0 (0 to 12) | 2.0 (0 to 10) | 2.0 (0 to 14) |
| Week 12 (Q2) | 4.0 (0 to 16) | 4.0 (0 to 24) | 4.0 (0 to 24) | 4.0 (0 to 17) | 4.0 (0 to 15) |
| Week 12 (Q3) | 1.0 (0 to 19) | 3.0 (0 to 24) | 3.0 (0 to 20) | 2.0 (0 to 24) | 2.0 (0 to 18) |
RUD evaluates dementia participants utilization of formal, informal healthcare resources, including hospitalizations, doctor visits, living assistance, time spent by nonprofessional caregivers. Information on days caregiver spent assisting participant from interviews during Stage 1 is reported for outcome measure, where following questions (Q), Q1= During last 30 days, how many days did you spend providing these (toilet visits, eating, dressing, grooming, walking, bathing) services to participant?; Q2= On typical care day during last 30 days, how much time per day did you assist participant with tasks such as shopping, food preparation, housekeeping, laundry, transportation, taking medication, managing financial matters?; Q3= During last 30 days, how many days did you spend providing these services (supervising) to the participant?. Data is collected for the treatment arm groups as pre-specified in the protocol for this outcome measure.
| days | Stage 1: Placebo | Stage 1: AVP-786-18 d6-DM 18 mg/Q 4.9 mg | Stage 1: AVP-786-28 d6-DM 28 mg/Q 4.9 mg |
|---|---|---|---|
| Week 6 (Q1) | 30.0 (0 to 30) | 30.0 (0 to 30) | 30.0 (0 to 30) |
| Week 6 (Q2) | 30.0 (0 to 30) | 30.0 (0 to 39) | 30.0 (4 to 30) |
| Week 6 (Q3) | 30.0 (0 to 30) | 30.0 (0 to 30) | 30.0 (0 to 30) |
RUD evaluates dementia participants utilization of formal, informal healthcare resources, including hospitalizations, doctor visits, living assistance, time spent by nonprofessional caregivers. Information on days caregiver spent assisting participant from interviews during Stage 1 is reported for outcome measure, where following questions (Q), Q1= During last 30 days, how many days did you spend providing these (toilet visits, eating, dressing, grooming, walking, bathing) services to participant?; Q2= On typical care day during last 30 days, how much time per day did you assist participant with tasks such as shopping, food preparation, housekeeping, laundry, transportation, taking medication, managing financial matters?; Q3= During last 30 days, how many days did you spend providing these services (supervising) to the participant?. Data is collected for the treatment arm groups as pre-specified in the protocol for this outcome measure.
| days | Stage 1: Placebo to Stage 2: Placebo | Stage 1: Placebo to Stage 2: AVP-786 18 mg | Stage 1: Placebo to Stage 2: AVP-786 28 mg |
|---|---|---|---|
| Week 12 (Q1) | 30.0 (0 to 30) | 30.0 (0 to 30) | 30.0 (0 to 30) |
| Week 12 (Q2) | 30.0 (0 to 30) | 30.0 (0 to 30) | 30.0 (0 to 30) |
| Week 12 (Q3) | 30.0 (0 to 30) | 30.0 (0 to 30) | 30.0 (0 to 30) |
Collected over Start of treatment up to Week 16 (End of treatment plus 30 days). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 1/194 (0.5%) | 6/194 (3.1%) | 84/194 (43.3%) |
| AVP-786-18 | 3/156 (1.9%) | 17/156 (10.9%) | 78/156 (50%) |
| AVP-786-28 | 1/159 (0.6%) | 7/159 (4.4%) | 71/159 (44.7%) |
| Event | Placebo | AVP-786-18 | AVP-786-28 |
|---|---|---|---|
| Urinary tract infectionInfections and infestations | 2/194 | 2/156 | 1/159 |
| Alcohol poisoningInjury, poisoning and procedural complications | 0/194 | 2/156 | 0/159 |
| Cerebrovascular accidentNervous system disorders | 0/194 | 2/156 | 0/159 |
| Atrial fibrillationCardiac disorders | 2/194 | 0/156 | 0/159 |
| Abdominal painGastrointestinal disorders | 0/194 | 1/156 | 0/159 |
| Non-cardiac chest painGeneral disorders | 0/194 | 1/156 | 0/159 |
| EpididymitisInfections and infestations | 0/194 | 1/156 | 0/159 |
| SepsisInfections and infestations | 0/194 | 1/156 | 0/159 |
| FallInjury, poisoning and procedural complications | 0/194 | 1/156 | 1/159 |
| Femoral neck fractureInjury, poisoning and procedural complications | 0/194 | 1/156 | 0/159 |
| Event | Placebo | AVP-786-18 | AVP-786-28 |
|---|---|---|---|
| FallInjury, poisoning and procedural complications | 12/194 | 14/156 | 12/159 |
| DiarrhoeaGastrointestinal disorders | 5/194 | 10/156 | 7/159 |
| HeadacheNervous system disorders | 3/194 | 10/156 | 2/159 |
| Urinary tract infectionInfections and infestations | 9/194 | 9/156 | 5/159 |
| AgitationPsychiatric disorders | 10/194 | 4/156 | 7/159 |
| SomnolenceNervous system disorders | 7/194 | 6/156 | 4/159 |
| ContusionInjury, poisoning and procedural complications | 4/194 | 5/156 | 2/159 |
| DizzinessNervous system disorders | 5/194 | 5/156 | 5/159 |
| Sinus bradycardiaCardiac disorders | 1/194 | 4/156 | 2/159 |
| NauseaGastrointestinal disorders | 4/194 | 4/156 | 0/159 |
Baseline data were collected in members of the Stage 1 Modified Intent-to-Treat (mITT) Population, comprised of all participants randomized in the study who had at least one post-Baseline efficacy assessment.
| Age, Continuous(years) | Placebo | AVP-786-18 | AVP-786-28 | Total |
|---|---|---|---|---|
| Mean | 76.6 ± 7.92 | 73.8 ± 8.39 | 74.6 ± 7.69 | 75.4 ± 8.06 |
| Sex: Female, Male(Participants) | Placebo | AVP-786-18 | AVP-786-28 | Total |
|---|---|---|---|---|
| Female | 112 | 47 | 54 | 213 |
| Male | 79 | 47 | 43 | 169 |
| Race (NIH/OMB)(Participants) | Placebo | AVP-786-18 | AVP-786-28 | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 1 | 1 |
| Asian | 3 | 1 | 1 | 5 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 12 | 6 | 6 | 24 |
| White | 175 | 87 | 89 | 351 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 0 | 1 |
Showing the first 100 of 126 sites across 6 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2015 to primary completion in Jan 2019, 42 months.
Results were first posted in Feb 2023, 4 years after primary completion. A results delay was requested in Jan 2020.
Of 34 phase 3 interventional studies under Dementia, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 60. This study's 42 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Deudextromethorphan · Quinidine
Otsuka Pharmaceutical Development & Commercialization, Inc. →